Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Avacta Systems Dramatically Save Time on Formulation Studies in Korea

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
Optim 1000 microvolume protein analysis and characterization instrument from Avacta.

Scientists at the specialized biotech company PharmAbcine are completing formulation and stability studies in a fraction of the time thanks to an Optim 1000 microvolume protein analysis and characterization instrument from Avacta Analytical.

PharmAbcine was established in the Republic of Korea in 2008 specifically for the development of human monoclonal antibodies into drugs for the treatment of human diseases, including cancer and inflammatory diseases.

With one product already undergoing clinical trials for blocking angiogenesis in glioblastomas, and a second monoclonal in development stages, the Company is keen to use high throughput technologies where possible, as Dr Weon Sup Lee, Head of the R&D Center at PharmAbcine, explained.

“High throughput is very important in the development of drug formulations, especially for a small company like PharmAbcine. With the Optim 1000 we can simultaneously check conformational change and the aggregation status of our molecule. We now use it routinely for looking at formulation and stability, and for developing purification processes taking many different combinations of factors - pH, buffers, adjuvants - into account. The Optim 1000 is easy to use and requires small sample volumes, which is a real advantage. Unlike techniques such as dynamic light scattering, the samples do not need any pre treatment in order to get good results, so we save time and costs there too.”

Dr Lee concluded: “For our first product we used spectrophotometers and HPLC for the preformulation studies and it took several months. In contrast, the same process for our second molecule was completed within a week using the Optim 1000 with DOE (Design of Experiment). It is simply very fast and reliable.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!